/Investor DB

HBM Healthcare Investments — 2022 Investments

3 investments dated 2022 · listed companies and verified rows first · show all

Mineralys Therapeuticsmineralystx.comin𝕏NASDAQ: MLYSJun 2022

Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.

BiotechHealthtechRadnor, US

Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)BT Slingsby, MD, PhD, MPH(Founder)

BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)

Co-investorsAndera PartnersCatalys PacificHBM PartnersSamsara BioCapitalSR One Capital ManagementYsios Capital+3 more

Arriventarrivent.cominDec 2022

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHBM PartnersHongShan Capital GroupLAV+4 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Vascular Dynamics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.